Last reviewed · How we verify
ShengXian-QuYu Decoction
ShengXian-QuYu Decoction, marketed by China-Japan Friendship Hospital, is a traditional Chinese medicine with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique mechanism and primary indication, which are currently undisclosed but likely leverage traditional formulations for specific therapeutic benefits. The primary risk is the potential for increased competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | ShengXian-QuYu Decoction |
|---|---|
| Sponsor | China-Japan Friendship Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ICIAM Rehabilitation Program Study: A Randomized Controlled Trial (NA)
- SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ShengXian-QuYu Decoction CI brief — competitive landscape report
- ShengXian-QuYu Decoction updates RSS · CI watch RSS
- China-Japan Friendship Hospital portfolio CI